Genmab — Februar 2016
-
Nordea: Genmab. Buying opportunity in spite of cautious guidance. We forecast USD 300M Darzalex sales in 2016 and 1 Billion in 2017. Genmab to be more cautious. Trim target to 1080 from 1100.
-
Nordea expect strong pipeline news throughout 2016
-
godt at se at Novod holder fast - mon ikke det er en usddkk adjustment?
-
Formodentlig
-
tak for info MUFC O
-
God måndag på alla!
Har läst igenom helgens diskussioner här. Verkar riktigt bra inför bokslutet på onsdag. -
og god mandag til dig - god volumen i dag, men tilsyneladende også store sælgere
-
US er vistnok lukket i dag - måske udlandet ikke vil fanges med bukserne ned og benytter +dagen til at reducere (igenigen...)
-
mon ikke bare det er lidt usikre ben efter nogle solide kæberaslere
-
GEN er den eneste aktie i dag, som ulandet sælger markant ud i.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind